TITLE

Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)

AUTHOR(S)
Opal, Steven M.; Garber, Gary E.; LaRosa, Steven P.; Maki, Dennis G.; Freebairn, Ross C.; Kinasewitz, Gary T.; Dhainaut, Jean-Francois; Yan, S. Betty; Williams, Mark D.; Graham, Delores E.; Nelson, David R.; Levy, Howard; Bernard, Gordon R.
PUB. DATE
July 2003
SOURCE
Clinical Infectious Diseases;7/1/2003, Vol. 37 Issue 1, p50
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Clinical trials with novel therapeutic agents for severe sepsis have suggested that patients might respond differently depending on causative microorganism. Data from a large, placebo-controlled trial of recombinant human drotrecogin alfa (activated) (DrotAA) were analyzed by type of causative microorganism for treatment-associated differences in mortality, coagulopathy, and inflammatory response. Compared with placebo, mortality rates associated with DrotAA were consistently reduced for each microorganism group (gram-positive bacteria, gram-negative bacteria, mixed bacteria, fungi, other, and unknown microbial etiology), with a stratified relative risk (RR) of 0.80 (95% confidence interval [CI], 0.69-0.94). The greatest reduction in the mortality rate was for Streptococcus pneumoniae infection (RR, 0.56; 95% CI, 0.35-0.88). Levels of coagulation and inflammation biomarkers varied with different pathogens at study entry. Results demonstrate that DrotAA, administered as an adjunct to standard anti-infective therapy, can improve the rate of survival for patients who develop severe sepsis regardless of causative microorganism.
ACCESSION #
10364306

 

Related Articles

  • Multicenter, Postmarketing Assessment of Levofloxacin in the Treatment of Adults with Community-Acquired Pneumonia. Akpunonu, B.; Michaelis, J.; Uy, C. N.; Tennenberg, A. M.; Wiesinger, B. A.; Karim, R.; Marshall, J. Scott; Kahn, J. B. // Clinical Infectious Diseases;1/15/2004 Supplement 1, Vol. 38, pS5 

    This phase IV, multicenter, open-label trial was designed to provide confirmation of the efficacy and safety of levofloxacin, 500 mg once daily, in a large population of “real-world” patients with community-acquired pneumonia (CAP). For 410 (24%) of the 1730 patients in the...

  • Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults. Annane, Djillali; Bellissant, Eric; Bollaert, Pierre-Edouard; Briegel, Josef; Confalonieri, Marco; De Gaudio, Raffaele; Keh, Didier; Kupfer, Yizhak; Oppert, Michael; Meduri, G. Umberto // JAMA: Journal of the American Medical Association;6/10/2009, Vol. 301 Issue 22, p2362 

    The article discusses a study which investigated the risks and benefits of corticosteroid treatment in severe sepsis and septic shock. The study included 17 randomized and quasi-randomized trials of corticosteroids compared to placebo in adult patients. In 12 trials, study authors found that...

  • Medical Therapy of Otitis Media: Use, Abuse, Efficacy, and Morbidity. Bitnun, Ari; Allen, Upton D. // Journal of Otolaryngology;Nov/Dec1998 Supplement, Vol. 27, p26 

    Objective: Otitis media (OM) is one of the most common paediatric disorders encountered by primary care physicians. Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis are the principal pathogens responsible for OM. As a result of the increasing prevalence of...

  • Heparin prophylaxis did not increase mortality and was beneficial in adults with sepsis receiving drotrecogin alfa. Cook, Deborah // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p6 

    The article focuses on the equivalence clinical trial investigating if co-administration of heparin thromboprophylaxis is equivalent to placebo in adults with severe sepsis who are receiving drotrecogin alfa (activated) (DrotAA). The trial, conducted with 1994 patients who were 18 years of age,...

  • A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. French, Neil; Gordon, Stephen B.; Mwalukomo, Thandie; White, Sarah A.; Mwafulirwa, Gershom; Longwe, Herbert; Mwaiponya, Martin; Zijlstra, Eduard E.; Molyneux, Malcolm E.; Gilks, Charles F. // New England Journal of Medicine;3/4/2010, Vol. 362 Issue 9, p812 

    Background: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines...

  • Antibiotic Selection Pressure and Macrolide Resistance in Nasopharyngeal Streptococcus pneumoniae: A Cluster-Randomized Clinical Trial. Skalet, Alison H.; Cevallos, Vicky; Ayele, Berhan; Gebre, Teshome; Zhaoxia Zhou; Jorgensen, James H.; Zerihun, Mulat; Habte, Dereje; Assefa, Yared; Emerson, Paul M.; Gaynor, Bruce D.; Porco, Travis C.; Lietman, Thomas M.; Keenan, Jeremy D. // PLoS Medicine;Dec2010, Vol. 7 Issue 12, p1 

    Background: It is widely thought that widespread antibiotic use selects for community antibiotic resistance, though this has been difficult to prove in the setting of a community-randomized clinical trial. In this study, we used a randomized clinical trial design to assess whether macrolide...

  • Designs for research of High Dilutons in animal models: an update. Alecu, Adrian; Alecu, Mariana; Brezeanu, Romeo; Mărcuş, Gabriela; Adriana Cojocaru // International Journal of High Dilution Resarch;2010, Vol. 9 Issue 30, p5 

    This article discusses the series of tests on animal experimental models carried out by our group to evaluate the effect of homeopathic preparations selected according to traditional criteria of pathogenetic similarity. Our overall experience indicates that it is not difficult to carry out...

  • Research & Markets: R&D Trends: Sepsis -- Improvements in Clinical Trial Design and Advances in Biomarker Research Hold the Key to a Tailored Approach to Sepsis Therapy.  // Biomedical Market Newsletter;5/16/2011, p334 

    The article focuses on the announcement of Research & Market Ltd. regarding the addition of the report "R&D Trends: Sepsis: Improvements in Clinical Trial Design and Advances in Biomarker Research Hold the Key to a Tailored Approach to Sepsis Therapy" on their offering. It states that an...

  • Is there a place for placebo controlled trials of antiepileptic drugs? Shorvon, S.D.; Espir, M.L.E.; Steiner, T.J.; Dellaportas, C.I.; Rose, F. Clifford // British Medical Journal (Clinical Research Edition);11/9/1985, Vol. 291 Issue 6505, p1328 

    Examines the possibility of a placebo controlled trials on antiepileptic drugs in Great Britain. Uncertainty on the role of anticonvulsant drugs on epileptics; Impact of epileptic seizures on the psychology and social behavior of epileptics; Natural history of epilepsy.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics